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Introduction {#sec1}
============

Translocations of the mixed-lineage leukemia (*MLL*) gene produce over 120 different MLL fusion proteins (MLL-FPs) that cause aggressive acute leukemias, the most common one being the *MLL-AF4* fusion ([@bib2], [@bib26]). Despite much progress in the treatment of childhood leukemias, infants carrying *MLL* rearrangements have a very poor prognosis ([@bib33]); thus, improving therapies for MLL-FP patients remains an unmet need. Because MLL-FPs are considered to be the main drivers of leukemogenesis, their function regulating downstream target genes is key to understanding MLL-rearranged (MLLr) leukemias and for designing targeted therapies.

MLL-FPs retain several domains ([Figure 1](#fig1){ref-type="fig"}A) including a CXXC domain that binds specifically to unmethylated CpG (uCpG) DNA ([@bib6]), interaction sites with the multiple endocrine neoplasia type 1 (Menin) ([@bib38]) and lens epithelium-derived growth factor (LEDGF) proteins ([@bib37]), and an interaction with the polymerase-associated factor protein complex (PAFc) ([@bib29], [@bib31]). Recruitment of MLL-FPs to gene targets is thought to be controlled by Menin, LEDGF, and PAFc interactions as well as CXXC binding to uCpGs ([@bib29], [@bib31], [@bib32], [@bib37], [@bib38]). Supporting this, a minimal MLL-FP containing just the PWWP domain of LEDGF, the CXXC domain of MLL, and the transactivation domain of the fusion partner can transform bone marrow progenitors and recapitulate MLL-FP binding at a few select genes ([@bib32]). However, a minimal CXXC domain can be recruited to the *HoxA9* locus in the absence of a Menin/LEDGF interaction ([@bib29]), although others have suggested that the CXXC domain has no role in recruitment and instead protects uCpG sites from methylation ([@bib34]). Recent data also suggest that Menin is unimportant for wild-type MLL ([@bib10], [@bib22]), whereas LEDGF is required for MLL but not MLL-FP recruitment ([@bib40]). Thus, it still remains an open question exactly how MLL-FPs are recruited to particular gene targets.

MLL-FP recruitment is associated with increased histone 3 lysine 79 di- and tri-methylation (H3K79Me2/3) at target genes, an epigenetic mark associated with gene activation ([@bib5], [@bib18], [@bib21], [@bib28]). H3K79Me2/3 levels are controlled by the disruptor of telomeric silencing 1-like (DOT1L) protein ([@bib20]). In MLL-FP leukemias, DOT1L directly interacts with AF9 or ENL ([@bib7], [@bib30]), and can be mis-targeted to MLL-FP-bound genes where it is associated with inappropriate activation of gene expression ([@bib28]) ([Figure 1](#fig1){ref-type="fig"}B). A recent study analyzing MLL-ENL binding suggests that there are two distinct classes of binding: proximal (5′) or distal (3′) to the transcription start site, with proximal binding being particularly sensitive to DOT1L inhibition ([@bib15]). MLL-AF4 can also bind in broad regions of up to 100 kb that correlate with large domains of H3K4me3 ([@bib18]) and MLL-AF9 transformed mouse bone marrow cells display H3K79me2 peaks with a similar wide spatial distribution ([@bib5]). Despite all this work, there is no current consensus on whether the main activity of MLL-FPs is the recruitment of DOT1L or whether different binding patterns of MLL-FPs are associated with distinct functional outcomes.

Here, we reveal a strong co-dependent relationship between MLL-AF4 and Menin binding at a small number of target genes containing uCpGs. At a subset of these gene targets, we observe MLL-AF4 and Menin spreading that is bookended by uCpGs. These spreading targets are distinct from super-enhancers, are associated with high levels of gene transcription, have an aberrant H3K79me2/H3K36me3 signature, and are predictive of a poor overall survival in patients with acute lymphoblastic leukemia (ALL). These gene targets also display a remarkable dependence on H3K79me2 and the fusion protein for their sustained expression in leukemia. Together, this work shows that MLL-FP spreading occurs at genes important in MLL leukemogenesis and has the potential to act as a biomarker for therapeutic response.

Results {#sec2}
=======

MLL-AF4 Binds Exclusively to a Subset of uCpGs {#sec2.1}
----------------------------------------------

Using MLL(N) and AF4(C) chromatin immunoprecipitation sequencing (ChIP-seq) in the human MLL-AF4 SEM cell line ([Figure 1](#fig1){ref-type="fig"}C), we identified 4,427 peaks and a gene set of 2,597 unique genes ([Table S1](#mmc2){ref-type="supplementary-material"}). MLL(N) ChIP-seq replicates had 81% peaks in common ([Figure 1](#fig1){ref-type="fig"}D), which identified 96.4% promoter-bound MLL(N) gene targets from our original ChIP-seq dataset ([Table S1](#mmc2){ref-type="supplementary-material"}, "Overlaps"). This gave us high confidence in the reproducibility of our gene target identification. To test the specificity of the MLL-AF4 target set, we performed MLL-AF4 small interfering RNA (siRNA) knockdowns coupled with nascent RNA sequencing (RNA-seq) ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and MLL-AF4 ChIP-seq ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Our MLL-AF4 gene target set was significantly downregulated at most genes ([Figure S1](#mmc1){ref-type="supplementary-material"}A, p \< 0.01, Mann-Whitney U test) and lost MLL-AF4 ChIP-seq signal at 85% of target gene promoters ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Among the 15% of MLL-AF4 gene targets with no reduced ChIP-seq signal, one-third showed a significant change in gene expression following MLL-AF4 knockdown ([Figure S1](#mmc1){ref-type="supplementary-material"}C). This suggests that these targets are also directly regulated by MLL-AF4, even though they consist primarily of promoters with a low MLL(N) ChIP-seq signal ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

If the CXXC domain is essential for MLL-AF4 recruitment, we would expect all MLL-AF4 binding sites to occur at regions of uCpGs. To test this, we used a biotinylated CXXC affinity purification (Bio-CAP) assay ([@bib8]) for high-sensitivity detection of regions of uCpG dinucleotides in SEM cells, combined with an assay for transposase-accessible chromatin sequencing (ATAC-seq) ([@bib11]) to identify regions of open chromatin ([Figure 1](#fig1){ref-type="fig"}C). Similar to results using non-methylated CpG/methylated-CpG island recovery assay sequencing (CIRA/MIRA-seq) with MLL-AF6 ([@bib32]), all MLL-AF4 binding occurred at open uCpG regions ([Figure 1](#fig1){ref-type="fig"}E) with the highest uCpG enrichment occurring at the center of MLL-AF4 binding sites ([Figure S1](#mmc1){ref-type="supplementary-material"}E). However, MLL-AF4 binding occurred at only 20% of uCpG sites ([Figure 1](#fig1){ref-type="fig"}F), indicating that open uCpG sites alone are not sufficient for MLL-AF4 recruitment. The Venn diagram ([Figure 1](#fig1){ref-type="fig"}F) shows a few MLL-AF4 sites that do not overlap with uCpGs, but it is clear from the heatmap that all MLL-AF4 binding sites occur at uCpG sites. The discrepancy is likely due to the reduced sensitivity of peak-calling programs used for the Venn diagram analysis.

To determine whether other CXXC domain-containing proteins ("CXXC proteins" from now on) are also restricted to only a proportion of uCpG sites, we performed ChIP-seq for CFP1 (a CXXC protein member of the SET1 complex associated with gene activation), and KDM2B (a CXXC protein involved in the recruitment of the polycomb group repressive complex \[PRC\] \[[@bib14]\]), in SEM cells ([Figure 1](#fig1){ref-type="fig"}C). In contrast to MLL-AF4, CFP1 and KDM2B bound more ubiquitously to uCpG sites, being found at 50% and 89% of all uCpG sites, respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Because the CXXC domains of MLL-AF4, CFP1, and KDM2B are highly related ([@bib24]), the differences in the number of bound uCpGs may be due to other protein interactions influencing recruitment.

Genome-wide Recruitment of Menin Mirrors that of MLL-AF4 {#sec2.2}
--------------------------------------------------------

To investigate whether MLL-AF4-specific interactions contribute to uCpG binding, we analyzed two complexes thought to be involved in MLL-FP recruitment: Menin/LEDGF and PAFc ([Figures 1](#fig1){ref-type="fig"}A--1C). Except for a very few Menin binding sites ([Figure 1](#fig1){ref-type="fig"}G, very bottom of heatmap), we found that almost all MLL-AF4 binding sites overlap with detectable Menin binding ([Figure 1](#fig1){ref-type="fig"}G). Many MLL-AF4 binding sites had only low levels of detectable Menin ([Figure 1](#fig1){ref-type="fig"}G), and thus strict peak-calling parameters produce an MLL-AF4/Menin overlap at only a subset of binding sites ([Figure 1](#fig1){ref-type="fig"}H). However, when MLL-AF4 binding sites were separated into either high or low Menin binding, we saw a direct relationship between levels of Menin binding and levels of MLL-AF4 binding ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Furthermore, a direct comparison of MLL(N) and Menin ChIP-seq reads at MLL-AF4 binding sites showed a significantly strong positive correlation (r^2^ = 0.96) ([Figure 1](#fig1){ref-type="fig"}I), whereas neither KDM2B nor CFP1 binding correlated with Menin ([Figures 1](#fig1){ref-type="fig"}J and [S1](#mmc1){ref-type="supplementary-material"}H). Thus, an association with Menin represents a feature that may serve to restrict MLL-AF4 recruitment to a particular subset of uCpG sites.

ChIP-seq on two members of PAFc, PAF1 and LEO1 ([Figure 1](#fig1){ref-type="fig"}C), overlapped with less than one-half of MLL-AF4 binding sites, and 4,892 (78%) of PAFc binding sites had no MLL-AF4 binding ([Figure S1](#mmc1){ref-type="supplementary-material"}I). Thus, compared to Menin binding, there is very little evidence for an MLL-AF4:PAF1 association genome-wide ([Figure 1](#fig1){ref-type="fig"}H), but it is possible that PAFc is necessary for recruitment only at select sites.

The Menin:MLL-AF4 Interaction Is Sufficient for Recruitment {#sec2.3}
-----------------------------------------------------------

To directly test the functionality of the interactions between Menin, MLL-AF4, and potentially PAFc, we used a Tet-repressor (TetR) system (see [Figure 2](#fig2){ref-type="fig"}A legend) previously designed to investigate the recruitment of PRC proteins ([@bib9]). Using ChIP-qPCR, we detected binding of Menin but not PAF1 in the presence of TetR-MLL-AF4 but not the TetR-only control ([Figure 2](#fig2){ref-type="fig"}B, left versus right panel), and recruitment was lost upon treatment with doxycycline ([Figure 2](#fig2){ref-type="fig"}B, left panel, red line). Reciprocal experiments using TetR-Menin- and TetR-PAF1-expressing mESC lines transiently transfected with MLL-AF4 produced equivalent results ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Despite being able to recruit other members of PAFc, TetR-PAF1 was not sufficient to recruit MLL-AF4 ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Expression of different constructs was confirmed with either western blot or qPCR ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). It has been recently shown that knockdowns of LEDGF sometimes lead to an increase in MLL-FP binding ([@bib40]). Similar to Zhu et al., we noticed a slight increase in MLL(N) ChIP at TetO in the presence of *Ledgf* siRNA ([Figures S2](#mmc1){ref-type="supplementary-material"}F and S2G), although we were only able to achieve a 30% *Ledgf* knockdown at the RNA level ([Figure S2](#mmc1){ref-type="supplementary-material"}F).

Our results so far support previous models suggesting that Menin recruits MLL-FPs ([@bib38], [@bib39]), and contrasts with previous reports that suggest that PAFc can recruit MLL-FPs ([@bib29], [@bib31]) ([Figure 2](#fig2){ref-type="fig"}C). The TetR assay does not establish directionality of these interactions; thus, it is also possible that MLL-FPs can recruit Menin ([@bib12]), or that the two proteins co-stabilize each other, as has recently been suggested for LEDGF and wild-type MLL ([@bib40]). In addition, it is possible that a relatively weak MLL-AF4:PAFc interaction is stabilized by other interactions when it occurs at active genes. To explore these issues further, we performed MLL-AF4, PAF1, or Menin siRNA knockdowns in SEM cells ([Figures 2](#fig2){ref-type="fig"}D--2H). MLL-AF4 knockdowns have a strong effect on the binding of Menin to gene targets ([Figure 2](#fig2){ref-type="fig"}Gi) and a moderate but detectable effect on PAF1 binding ([Figure 2](#fig2){ref-type="fig"}Hi). Menin knockdowns reduce both MLL-AF4 and PAF1 binding to gene targets ([Figures 2](#fig2){ref-type="fig"}E--2Hii), whereas two different PAF1 siRNAs produce a similar result in that they reduce Menin binding slightly but have little effect on MLL-AF4 except at the *HOXA9* locus ([Figures 2](#fig2){ref-type="fig"}E--2Hiii and [S2](#mmc1){ref-type="supplementary-material"}H). Together, these data show that there is a complex co-recruitment relationship between MLL-AF4 and Menin, and that PAF1 does not have a major role in recruiting MLL-AF4 to most gene targets. However, MLL-AF4 either directly or indirectly, has a role in maintaining stable PAF1 binding at specific gene targets. To analyze MLL-AF4 function in further detail, we next tried to determine whether MLL-AF4 displayed distinct binding profiles at different subsets of genes.

Spreading of MLL-AF4 Marks a Subset of Highly Expressed Genes {#sec2.4}
-------------------------------------------------------------

An analysis of MLL-AF4 binding profiles revealed two patterns of binding. The majority of MLL-AF4 binding sites displayed narrow binding at the promoter and a normal pattern of H3K79me2 and H3K36me3 ([Figure 3](#fig3){ref-type="fig"}A). We also occasionally observed MLL-AF4 spreading greater than 4 kb into the gene body without exceeding the end of the gene, and this was associated with H3K79me2 spreading and a reduction or loss of H3K36me3 throughout the gene body ([Figure 3](#fig3){ref-type="fig"}B). Spreading was observed at 149 (3.4%) MLL-AF4 gene target isoforms (117 unique gene targets) in SEM cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [Table S2](#mmc1){ref-type="supplementary-material"}). A Gene Ontology analysis revealed that spreading occurred at genes involved in hematopoiesis as well as lymphocyte activation and differentiation, showing that it could have a role in leukemia initiation or maintenance ([Figure S3](#mmc1){ref-type="supplementary-material"}B). We confirmed that spreading was specific to MLL-AF4 using *MLL-AF4* siRNA knockdowns followed by ChIP-qPCR in regions of spreading at specific targets ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Spreading is reminiscent of broad MLL-AF4 binding domains at sites of broad H3K4me3 ([@bib18]), although we found that there was less than a 50% overlap between our spreading dataset and the MLL-AF4 target set originally identified by Guenther et al. ([Figure S3](#mmc1){ref-type="supplementary-material"}D).

To test whether MLL-AF4 spreading was a marker of significant functional activity, we analyzed nascent RNA-seq data and found that spreading MLL-AF4 targets showed significantly higher expression compared to targets of non-spreading MLL-AF4, or active gene targets bound by CFP1 (p \< 0.0001, two-tailed Mann-Whitney U test; [Figure 3](#fig3){ref-type="fig"}C). Spreading targets were also highly enriched for H3K79me2 at the 5′ end of the gene compared to non-spreading MLL-AF4 or non-MLL-AF4 targets ([Figure 3](#fig3){ref-type="fig"}D). The increased enrichment of H3K79me2 along with its spread into the gene body, strongly suggests that the H3K79me2 pattern observed is a consequence of spreading MLL-AF4.

Because broad MLL-FP binding domains have been observed previously ([@bib5], [@bib18]), one possibility is that spreading identifies bona fide MLL-AF4 target genes, whereas non-spreading peaks represent wild-type MLL and AF4 co-bound sites. To test this, we separated the MLL-AF4 siRNA nascent RNA-seq and ChIP-seq datasets ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D) into spreading and non-spreading target sets. We found that almost all spreading and non-spreading targets are bound by MLL-AF4, but spreading targets are more likely to be downregulated by a loss of MLL-AF4 ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). A recently generated FLAG tagged MLL-Af4 ChIP-seq experiment in CD34^+^ cord blood cells ([@bib23]) allowed us to unambiguously identify MLL-Af4 binding sites in a primary transformed cell. FLAG-MLL-Af4 ChIP-seq identified almost 3,000 MLL-Af4 gene targets, similar to the number we obtained in SEM cells ([@bib23]). FLAG-MLL-Af4 binding could be divided into both spreading and non-spreading targets, about 40%--50% of which overlapped with MLL-AF4 targets in SEM cells ([Figures S3](#mmc1){ref-type="supplementary-material"}G--S3I). Taken together, this suggests that MLL-AF4 can display both spreading and non-spreading binding patterns, but spreading gene targets are less common and are more significantly associated with a dependence on MLL-AF4 for their activation.

In order to better understand the significance of our spreading target set, we analyzed the expression profile of SEM spreading targets in two different patient cohorts and found that 64%--79% of SEM spreading targets are overexpressed in MLLr ALL patients ([Figures 3](#fig3){ref-type="fig"}E and 3F). Using a super-PC analysis ([@bib1]), we also found that there is a signature within the spreading target set that is predictive of a poor prognosis in patients ([Figures 3](#fig3){ref-type="fig"}G and 3H). Thus, MLL-AF4 spreading targets also have clinical significance in patients.

Spreading Is Common among MLL Fusion Proteins but Not Wild-Type MLL {#sec2.5}
-------------------------------------------------------------------

Because spreading is an important feature of MLL-AF4 binding, we investigated how common spreading is for other MLL-FPs. MLL(N) ChIP-seq in the MLL-AF6 cell line ML-2 detects the fusion protein unambiguously due to a deletion of the wild-type *MLL* allele. Spreading for MLL-AF6 was observed at 47 (43.1%) gene target isoforms ([Figure 4](#fig4){ref-type="fig"}A; [Table S3](#mmc1){ref-type="supplementary-material"}), and similar to MLL-AF4, these spreading targets displayed a significant increase in H3K79Me2 compared to non-spreading MLL-AF6 targets ([Figure 4](#fig4){ref-type="fig"}B). The high percentage of spreading peaks within the MLL-AF6 set is due to the low number (109) of total MLL-AF6 binding events in ML-2 cells. Using MLL(N) ChIP-seq, spreading was also observed in MV4;11 (MLL-AF4), KOPN-8 (MLL-ENL), and THP-1 (MLL-AF9) MLLr cell lines ([Figures 4](#fig4){ref-type="fig"}C and 4D; [Table S1](#mmc2){ref-type="supplementary-material"}). ER-tagged MLL-ENL ([@bib15]), biotin-tagged MLL-AF9 ([@bib5]), MLL-AF4 in MV4;11 cells ([@bib40]), MLL-AF4 in patient cells (this study), and FLAG-MLL-Af4 in CD34^+^ cells ([@bib23]) also displayed spreading ([Figures 4](#fig4){ref-type="fig"}E, 4F, and [S4](#mmc1){ref-type="supplementary-material"}A--S4E). The spreading pattern of MLL-AF4 in SEM cells often closely resembles the spreading pattern of MLL-AF4 in patient cells or in FLAG-MLL-Af4 cells at common gene targets ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E), suggesting there may be a common mechanism for spreading among these diverse samples.

Importantly, wild-type MLL spreading is not observed in non-MLLr leukemia cell lines (RCH-ACV or CCRF-CEM), at wild-type MLL binding sites in SEM cells ([Figures 4](#fig4){ref-type="fig"}C and 4D), or for wild-type MLL(C) in MV4;11 cells ([@bib40]) ([Figure S4](#mmc1){ref-type="supplementary-material"}C). MLL-AF4 displays spreading in primary patient cells, but there was no wild-type MLL spreading in the relevant normal human hematopoietic cells from either cord blood (CB) or second-trimester fetal bone marrow (FBM) ([Figures 4](#fig4){ref-type="fig"}E, 4F, [S4](#mmc1){ref-type="supplementary-material"}A, and S4D). These results show spreading is specifically associated with MLL-FPs.

Some Individual Spreading Gene Targets Have Altered Gene Expression, Reduced DNA Methylation Patterns, and Individual Poor Prognoses in Patients {#sec2.6}
------------------------------------------------------------------------------------------------------------------------------------------------

To better understand the clinical significance of individual spreading targets, we analyzed nine common targets from five MLLr leukemia cell lines ([Figure 4](#fig4){ref-type="fig"}G; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). High expression of *ARID2*, *JMJD1C*, *MBNL1*, *MEF2C*, or *RUNX2* alone is associated with at least one indicator of poor prognosis in ALL patients ([Table S4](#mmc1){ref-type="supplementary-material"}), and *CPEB2*, *MBNL1*, *RUNX2*, and *ZEB2* are all specifically overexpressed in MLL-FP leukemias ([Figures 4](#fig4){ref-type="fig"}H and [S5](#mmc1){ref-type="supplementary-material"}A; [Table S5](#mmc3){ref-type="supplementary-material"}). Interestingly, *RUNX2*, *MBNL1*, *JMJD1C*, *SENP6*, *MEF2C*, and *ZEB2* are also hypomethylated in MLL-FP samples compared to either normal cells or other leukemias ([Figure S5](#mmc1){ref-type="supplementary-material"}B; not shown). Although these data show that some MLL-FP spreading targets can individually have an important role in human leukemias, there does not seem to be a single key set of spreading targets that are necessarily found in all MLL-FP samples. However, taken in total, the data show that MLL-FP spreading is an indicator of particularly significant MLL-FP activity.

Spreading Correlates with Menin and MLL-AF4 Complex Components {#sec2.7}
--------------------------------------------------------------

To better understand MLL-FP spreading, we analyzed whether spreading is related to other MLL-AF4 complex components ([Figure 5](#fig5){ref-type="fig"}A). When all MLL-AF4 spreading targets were sorted by length, the ChIP-seq signal of MLL(N) and AF4(C) generated a characteristic curve shape ([Figure 5](#fig5){ref-type="fig"}B, panels 1 and 2). Interestingly, MLL-AF4 spreading is punctuated by uCpG sites, with the beginning and end of spreading domains demarcated by uCpG sites ([Figures 5](#fig5){ref-type="fig"}A and 5B, panel 3). This indicates a role for the CXXC domain in stabilizing spreading and agrees with the hypomethylation observed at spreading MLL-AF4 targets in patients ([Figure S5](#mmc1){ref-type="supplementary-material"}B). This is an important role for the CXXC domain within the context of MLL-AF4 because neither KDM2B nor CFP1 showed the same spreading pattern, even though they both bind to uCpGs ([Figures 5](#fig5){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}A). The majority of uCpG regions under spreading peaks were within 1--2 kb of each other and rarely exceeded 4 kb, with 7 kb being the greatest distance observed ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Therefore, the proximity of uCpG sites to each other under the spreading peaks appears to be important and may be a limiting factor in determining the degree of spreading. If true, this also suggests that spreading may be non-random, and only genes with a clustered uCpG landscape downstream of their promoter are amenable to spreading.

Spreading was not simply a result of an association with basal transcription factors because neither RNAPII nor members of PAFc showed the same spreading pattern; instead, they extended beyond the spreading domain to the end of the gene ([Figures 1](#fig1){ref-type="fig"}C, [5](#fig5){ref-type="fig"}A, and [S6](#mmc1){ref-type="supplementary-material"}C). Conversely, both Menin and ENL displayed identical spreading patterns to MLL-AF4 ([Figures 1](#fig1){ref-type="fig"}C, [5](#fig5){ref-type="fig"}A and 5B, panels 4 and 5). Our observation that Menin knockdowns reduce MLL-AF4 binding at spreading gene targets ([Figures 2](#fig2){ref-type="fig"}E--2G) supports the idea that there is a role for Menin in stabilizing spreading. In conclusion, we envisage a model whereby CXXC-mediated weak binding of the fusion protein at low-CG density uCpG sites in the gene body can be stabilized by CXXC-mediated recruitment to the CG-rich uCpGs at promoters ([Figure 5](#fig5){ref-type="fig"}C). However, this depends on the weak binding sites occurring in close proximity to the promoter and each other, with Menin or ENL facilitating stabilization through a bridging mechanism ([Figure 5](#fig5){ref-type="fig"}C).

Spreading MLL-AF4 Represents a Subset of Broad H3K4me3 Distinct from Super-Enhancers {#sec2.8}
------------------------------------------------------------------------------------

Several recent studies have characterized broad binding chromatin domains as markers of functional significance, including super-enhancers ([@bib25], [@bib35]) and broad regions of H3K4me3 ([@bib3]). Whereas genes associated with super-enhancers were shown to correlate with increased expression, genes marked by broad H3K4me3 showed an increase in transcriptional consistency, i.e., less variation in transcription rate between replicates as determined by RNA-seq and nascent RNA-seq, as well as an increase in gene expression ([@bib3]). Here, we wanted to determine whether MLL-AF4 spreading domains were related to either super-enhancers or broad H3K4me3 peaks.

First, we characterized super-enhancers and broad H3K4me3 domains in SEM cells using the same criteria as the original studies ([Figures S6](#mmc1){ref-type="supplementary-material"}D--S6G). Almost all regions of spreading MLL-AF4 were distinct from super-enhancers, but the majority (87%) of spreading MLL-AF4 gene targets were a subset of broad H3K4me3 gene targets ([Figure 5](#fig5){ref-type="fig"}D). Despite being distinct from super-enhancers, spreading MLL-AF4 correlated with MED1 and BRD4 binding as well as H3K27Ac ([Figure 5](#fig5){ref-type="fig"}E, panels 1--3). The major difference between MLL-AF4 spreading domains and super-enhancers was the lack of H3K4me1 enrichment; instead, spreading overlaps with H3K4me3 and H3K79me2 ([Figure 5](#fig5){ref-type="fig"}E, panels 4--6).

Similar to past work ([@bib3]), gene targets of the 5% broadest H3K4me3 peaks in SEM cells showed a significant increase in transcriptional consistency compared to genes marked by the remaining 95% of H3K4me3 peaks (p \< 0.0001, Mann-Whitney U test, [Figure S6](#mmc1){ref-type="supplementary-material"}H). As a whole, gene targets of MLL-AF4 showed a significant increase in transcriptional consistency compared to H3K4me3-marked genes (p \< 0.0001, Mann-Whitney U test; [Figure S6](#mmc1){ref-type="supplementary-material"}I), suggesting that maintaining gene regulation within narrow limits could be an important property of MLL-AF4 controlled gene expression crucial for the leukemia. However, spreading MLL-AF4 gene targets did not show increased transcriptional consistency compared to all MLL-AF4 gene targets ([Figure S6](#mmc1){ref-type="supplementary-material"}I); thus, this was not a feature specific to spreading. Based on the signature of histone marks and protein associations, spreading MLL-AF4 represents a hybrid of broad H3K4me3 domains and super-enhancers, with transcriptional properties such as high expression ([Figure 3](#fig3){ref-type="fig"}C) more similar to super-enhancers.

Gene Targets of Spreading MLL-AF4 Display Increased Sensitivity to DOT1L Inhibition {#sec2.9}
-----------------------------------------------------------------------------------

If it is possible to target spreading MLL-AF4 target genes, it is likely that this would have a strong and specific effect on the inhibition of leukemia maintenance. Because spreading MLL-AF4 targets are marked with high levels of H3K79me2 ([Figure 3](#fig3){ref-type="fig"}D), we wanted to determine whether they are particularly sensitive to the DOT1L inhibitor EPZ-5676 ([@bib13]). Treatment of SEM cells with 2 μM EPZ-5676 for 7 days produced an almost complete loss of the H3K79me3 mark for all genes tested ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Using nascent RNA-seq, we identified 2,462 downregulated genes, 84% of which were marked by H3K79me2 ([Figure 6](#fig6){ref-type="fig"}A) and that included a number of spreading targets (e.g., *CDK6*; [Figure 6](#fig6){ref-type="fig"}B). As a group, over 50% of spreading targets were downregulated following EPZ-5676 treatment compared to only 16% of non-spreading MLL-AF4 targets and 23% of H3K79me2-marked genes (p \< 0.0001, two-tailed Fisher's exact test; [Figure 6](#fig6){ref-type="fig"}C). Furthermore, spreading MLL-AF4 targets were among those that showed the greatest downregulation, even compared to genes that had similar levels of high expression ([Figure 6](#fig6){ref-type="fig"}D). Spreading MLL-AF4 gene targets were also significantly more downregulated in response to EPZ-5676 compared to non-spreading MLL-AF4 gene targets (p \< 0.0001, Mann-Whitney U test; [Figure 6](#fig6){ref-type="fig"}E). Therefore, spreading MLL-AF4 targets are among the most sensitive to treatment with EPZ-5676 when compared to all other genes. Using a randomly selected group of genes with levels of H3K79me2 similar to those of spreading MLL-AF4 targets ([Figure S7](#mmc1){ref-type="supplementary-material"}B), we also found that spreading MLL-AF4 targets were significantly more downregulated after EPZ-5676 treatment ([Figure S7](#mmc1){ref-type="supplementary-material"}C, top and bottom; p \< 0.0001 and p \< 0.01, respectively; Mann-Whitney U test). Therefore, genes marked by spreading MLL-AF4 show increased sensitivity to EPZ-5676 through a mechanism not simply determined by high levels of H3K79me2. Interestingly, spreading targets that overlapped with either broad H3K4me3 or super-enhancers were significantly more sensitive to DOT1L inhibition than spreading MLL-AF4 targets alone ([Figure S7](#mmc1){ref-type="supplementary-material"}D). This indicates that there are further subdivisions of activity within spreading targets themselves, something that may explain recent results looking at DOT1L and BRD4 cooperation ([@bib17]).

As well as being particularly sensitive to a loss of H3K79me2/3, spreading MLL-AF4 gene targets were significantly downregulated compared to non-spreading and non-MLL-AF4 targets by MLL-AF4 siRNA treatment (p \< 0.0001, two-tailed Mann Whitney U test; [Figure 6](#fig6){ref-type="fig"}F). Therefore, the increased gene expression observed at MLL-AF4 spreading targets is significantly linked to both MLL-AF4 and H3K79me2 and is more likely to be downregulated by DOT1L inhibition.

Sensitivity of Spreading Gene Targets Provides a Rationale for Combination Therapy Using DOT1L Inhibitors {#sec2.10}
---------------------------------------------------------------------------------------------------------

It seems unlikely that a single drug alone will be effective in treating MLL-AF4 leukemias. Even among MLL-AF4 spreading targets, some gene targets have an increased sensitivity to a loss of H3K79me2 ([Figures 7](#fig7){ref-type="fig"}A and 7B; [Table S6](#mmc1){ref-type="supplementary-material"}). We recently showed that the BCL-2-specific protein inhibitor ABT-199 synergizes with DOT1L inhibitors ([@bib4]), potentially because BCL-2 protein levels are not strongly affected by DOT1L inhibitor concentrations that affect more sensitive targets such as CDK6 or BCL11A ([Figure 7](#fig7){ref-type="fig"}B). Because Menin is partly responsible for spreading (see [Figures 2](#fig2){ref-type="fig"}E--2G and [5](#fig5){ref-type="fig"}A--5C), the use of Menin inhibitors represents another way to target sensitive MLL-AF4 spreading genes (see [Figure S7](#mmc1){ref-type="supplementary-material"}E). In an extension of our earlier work, we find that there is a strong synergy between ABT-199 and the DOT1L inhibitors EPZ5676 and SGC0946, as well as a strong synergistic interaction between the Menin inhibitor MI-503 ([@bib10]) and ABT-199 ([Figures 7](#fig7){ref-type="fig"}C--7F; combination index \[CI\] \< 1; calculations as described in [@bib27]). Thus, carefully choosing different drug combinations may increase their effectiveness at disrupting MLL-FP leukemic growth.

Discussion {#sec3}
==========

In this study, we have found that uCpGs strongly correlate with the highest occupancy of MLL-AF4 binding and that MLL-AF4 and Menin co-stabilize each other's binding to gene targets. This mirrors recent findings of co-dependent stabilization between wild-type MLL and LEDGF ([@bib40]), which would suggest an independent role for LEDGF in wild-type MLL function, as previous reports indicate that Menin and wild-type MLL regulate distinct gene targets ([@bib22]). Zhu et al. have also shown that loss of LEDGF actually increases MLL-FP recruitment ([@bib40]), which is partly supported by our *Ledgf* knockdown experiment ([Figure S2](#mmc1){ref-type="supplementary-material"}G). We have also shown that there is no direct connection between MLL-AF4 recruitment and PAFc, suggesting that past observations of MLL-FP dependence on PAFc ([@bib29], [@bib31]) may have been due to indirect effects, or perhaps PAFc is only required for binding of MLL-FPs at specific gene targets such as *HOXA9*.

Previous studies have indicated that MLL-FP binding can be associated with broad chromatin domains ([@bib5], [@bib18]) or divided into two classes, with 5′ binding indicating a dependence on H3K79me2 ([@bib15]). Our results suggest that it is not the presence of MLL-AF4 and H3K79me2/3 that is most predictive of a dependence on H3K79me2, but the presence of MLL-AF4 spreading. Our observations also show that spreading strongly correlates with Menin and ENL binding and occurs across uCpG landscapes in the gene body that are within close proximity to the gene promoter. Unmethylated CpG regions in gene bodies typically display a relatively low CG density, which is possibly why we do not observe other CXXC proteins binding in the gene body. Therefore, spreading of MLL-FPs may be made possible by Menin/ENL-mediated stabilization at gene body uCpG regions where uCpG density is too low for a strong CXXC-uCpG interaction. Although wild-type MLL can also interact with Menin, a co-operation with fusion partner proteins such as ENL may generate complexes that permit MLL-FP dimerization ([@bib30], [@bib39]) and through this mechanism create a spreading domain of MLL-FP that is anchored by CXXC-uCpG interactions in close proximity to each other, something that is unavailable to wild-type MLL.

It is unknown whether an ability to spread into the body of particular gene targets drives higher expression and initiates progression of leukemia or whether these gene targets are already highly expressed and the active chromatin landscape is simply a pre-requisite for facilitating spreading. Nevertheless, in the context of these remaining questions, our study has revealed that spreading of MLL-AF4 defines the expression of a subset of genes that are important for leukemia and are characterized by gene activation that is predictive of a poor prognosis. These target genes are particularly sensitive to DOT1L inhibition, which provides a new molecular rationale for the specificity of DOT1L or Menin inhibition in MLL-AF4 leukemias, and the possibility of combining this with drugs that target less sensitive spreading targets such as those that target BCL-2.

Experimental Procedures {#sec4}
=======================

Cell Lines, Cultures, and Drug Treatment Studies {#sec4.1}
------------------------------------------------

Cell lines, culture methods, and drug treatment protocols used in this study are listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. CB was collected under the auspices of a National Research Ethics Service-approved study with written informed consent. Human fetal bone samples were obtained through the Human Development Biology Resource (<http://www.hdbr.org>).

Western Blot Analysis {#sec4.2}
---------------------

Western blot analysis was performed as previously described ([@bib36]). Antibodies used for western blot analysis are listed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

ChIP Assays and ChIP-Seq {#sec4.3}
------------------------

ChIP and ChIP-seq experiments were performed as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} and as previously described ([@bib4], [@bib36]).

TetR Recruitment System {#sec4.4}
-----------------------

For the TetR recruitment assay, we used the previously engineered Tet-operon (TetO) mESC line ([@bib9]). *MLL-AF4*, *Menin*, and *PAF1* cDNA were inserted downstream of the FS2-TetR coding sequence in the original pCAGFS2TetR vector, by ligation-independent cloning (LIC). Plasmids were transfected into TetO mESCs using Lipofectamine 2000, and clones stably expressing TetR fusions were selected using puromycin (1 μg/mL), or *MLL-AF4* cDNA was transiently transfected into mESCs at 60%--70% confluency using Lipofectamine 2000. Cells were collected 24 hr after transfection.

Gene Targets and Spreading Peaks {#sec4.5}
--------------------------------

ChIP-seq peaks were called as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Gene targets were defined as any gene where the transcription start site (TSS) overlapped directly with a peak. A peak was classed as spreading if it overlapped the TSS of a gene and extended over 4 kb from the TSS into the gene body without going beyond the transcription end site (TES) of the gene. If a peak exhibited spreading at two different genes (or isoforms with different TSS co-ordinates), both spreading-gene pairs were kept.

Nascent RNA-Seq {#sec4.6}
---------------

Nascent RNA-seq and gene expression analysis was performed as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Survival Analysis {#sec4.7}
-----------------

Clinical datasets and survival analyses are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistics {#sec4.8}
----------

Data were analyzed using Fisher's exact test, Wilcoxon test, and Mann-Whitney U test, where appropriate. Results were deemed significant if p \< 0.05. Unless otherwise indicated, data are shown as mean ± SD. This paper analyzed datasets from GEO: [GSE13313](ncbi-geo:GSE13313){#intref0015}, [GSE28460](ncbi-geo:GSE28460){#intref0020}, [GSE29130](ncbi-geo:GSE29130){#intref0025}, [GSE34861](ncbi-geo:GSE34861){#intref0030}, [GSE73528](ncbi-geo:GSE73528){#intref0035}, [GSE74812](ncbi-geo:GSE74812){#intref0040}, and [GSE84116](ncbi-geo:GSE84116){#intref0045}; and ArrayExpress: [E-MTAB-3593](array-express:E-MTAB-3593){#intref0050} (for a detailed list of datasets, see [Table S7](#mmc1){ref-type="supplementary-material"}).
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![MLL-AF4 Is Recruited Exclusively to uCpG Regions Bound by Menin\
(A) Schematic showing MLL and MLL fusion protein interaction sites.\
(B) Schematic showing the MLL-AF4 core complex.\
(C) Example ChIP-seq, Bio-CAP-seq, and ATAC-seq tracks in SEM cells.\
(D) Venn diagram showing overlap between two biological replicates of MLL(N) ChIP-seq.\
(E) Heatmap showing ChIP-seq, Bio-CAP-seq, and ATAC-seq reads at all 4,427 MLL-AF4 binding sites in SEM cells. Scale bar represents tags per base pair (bp) per 10^7^ reads.\
(F) Venn diagram showing overlap between MLL-AF4 binding sites and uCpG regions (Bio-CAP-seq and ATAC-seq) in SEM cells.\
(G) Heatmap showing MLL(N), AF4(C), and Menin ChIP-seq reads at all MLL-AF4 binding sites in SEM cells. Scale bar as in (E).\
(H) Venn diagram showing overlap between MLL-AF4, PAF1, and Menin binding sites in SEM cells.\
(I and J) Scatterplot showing a strong correlation (r^2^ = 0.96) between MLL(N) and Menin ChIP-seq signal at all MLL-AF4 peaks (I) in SEM cells and a weak correlation between Menin and CFP1 (r^2^ = 0.27) at all CFP1 peaks (J) in SEM cells.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![The MLL-AF4:Menin Interaction Is Sufficient but Not Necessary for Recruitment\
(A) The Tet-repressor (TetR) recruitment system. An array of Tet-operator (TetO) sequences was centrally inserted into a BAC lacking known promoter, enhancer, or uCpG features, and the BAC was inserted into chromosome 8 of mouse embryonic stem cells (mESCs) ([@bib9]). Proteins of interest fused to the TetR can be anchored at the TetO array. The TetR-TetO interaction can be disrupted with doxycycline treatment, allowing one to test whether recruitment of a specific protein is dependent on the continuous presence of a particular TetR fusion.\
(B) ChIP-qPCR showing the binding of TetR-MLL-AF4 (using FS2 \[TetR\] and MLL(N) antibody), Menin, and PAF1 in TetO mESCs transfected with TetR-MLL-AF4 (left panel) and in TetR-only control mESCs (right panel). Error bars represent the SD of two biological replicates. Red line, with doxycycline.\
(C) The TetR experiments indicate that there is a strong interaction between MLL-AF4 and Menin and an undetectable interaction between MLL-AF4 and PAF1.\
(D) SEM cells were treated with MLL-AF4, Menin, or PAF1 siRNAs, and individual representative western blots from the experiments in E--H are shown.\
(E--H) MLL-N (E), AF4-C (F), Menin (G), and PAF1 (H) ChIP in control (black bars) and siRNA-treated (gray bars) SEM cells as follows: column i, MLL-AF4 siRNA; column ii, Menin siRNA; and column iii, PAF1 siRNA. Note that the control samples are the same between PAF1\#1 siRNA and PAF1\#2 siRNA (see [Figure S2](#mmc1){ref-type="supplementary-material"}H) experiments as these were performed in parallel. Error bars represent the SD of at least three biological replicates.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![MLL-AF4 Spreading Marks a Subset of Highly Expressed Genes\
(A and B) Example ChIP-seq tracks showing promoter-restricted (A) or spreading (B) of MLL-AF4, H3K79me2, and H3K36me3 in SEM cells.\
(C) Box-and-whisker plot showing the median and interquartile (IQ) range of gene expression of spreading MLL-AF4 gene targets (n = 149) compared to non-spreading MLL-AF4 targets (n = 2,878) and CFP1 targets (n = 6,147). Gene expression, normalized to *GAPDH* expression, is derived from four biological replicates of nascent RNA-seq in SEM cells. ^∗∗∗∗^p \< 0.0001, two-tailed Mann-Whitney U test.\
(D) Composite binding plot of H3K79me2 ChIP-seq reads at the TSS of gene targets of spreading MLL-AF4 (red), non-spreading MLL-AF4 (blue), and non-MLL-AF4 targets that are marked by H3K79me2 (green).\
(E and F) Heatmap expression data showing overexpression of 79% (E, COG P9906 patients \[[@bib19]\]) or 64% (F, ECOG 2993 patients \[[@bib16]\]) of SEM spreading targets in MLL patients (MLLr) compared to the ALL patient subsets indicated.\
(G and H) Super-PC analysis ([@bib1]) using the spreading-gene target list showing relapse-free survival (RFS) of ALL patients (G, COG P9906 \[[@bib19]\]) and overall survival (OS) of ALL patients (H, ECOG 2993 \[[@bib16]\]) classified by either high- or low-risk scores computed using the spreading MLL-AF4 gene targets in a super-PC model; see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, Survival Analysis, for details.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![MLL-FP Spreading Occurs in Multiple in MLL Leukemias\
(A) Spreading MLL-AF6 peaks were defined as peaks that extend greater than 4 kb from the TSS into the gene body without going beyond the end of the gene. Using these criteria, 47 spreading MLL-AF6 peaks were identified in ML-2 cells ([Table S2](#mmc1){ref-type="supplementary-material"}).\
(B) Composite binding plot of H3K79me2 ChIP-seq reads at the TSS of gene targets of spreading MLL-AF6 (red) and non-spreading MLL-AF6 (blue) in ML-2 cells.\
(C) Example ChIP-seq tracks of MLL(N) in MLL-FP and germline MLL cell lines.\
(D) Heatmaps of MLL(N) ChIP-seq reads from different MLL-FP cell lines as well as wild-type MLL in SEM cells and in non-MLLr cell lines. Red dotted line indicates spreading across a 10-kb window. Scale bar represents tags per base pair per 10^7^ reads.\
(E) Example ChIP-seq tracks of MLL(N) showing spreading in MLL-AF4 patient cells (top) compared to wild-type MLL in mononuclear cells derived from cord blood (middle) and fetal bone marrow (bottom).\
(F) Heatmaps showing MLL(N) ChIP-seq reads from the experiments in (E); scale and red line as in (D).\
(G) Venn diagram showing the overlap between gene targets of spreading MLL(N) ChIP-seq several MLLr cell lines.\
(H) *CPEB2*, *MBNL1*, and *RUNX2* are overexpressed in MLL-AF4 and other MLL-FP patients compared to different patient samples and normal pre-B cells. Each dot indicates an individual patient sample. Data are taken from an ECOG E2993 clinical trial ([@bib16]). Dark red asterisk (^∗^) indicates a significant difference compared to MLL-AF4, and pink asterisk (^∗^) indicates a significant difference compared to the MLL-FP group (which includes MLL-ENL \[6\], MLL-AF9 \[1\], and MLL-EPS15 \[1\]). ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05. A two-tailed Wilcoxon test was used to calculate p values, and p values for the different comparisons are listed in [Table S5](#mmc3){ref-type="supplementary-material"}.\
See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Spreading Correlates with Members of the Menin:LEDGF and Super-Elongation Complexes\
(A) Example ChIP-seq tracks at *SUPT3H* in SEM cells.\
(B) Heatmap of MLL-AF4, Bio-Cap, Menin, and ENL signal at all 149 spreading MLL-AF4 targets, ordered by length of spreading peak. Scale bar represents tags per bp per 10^7^ reads.\
(C) Schematic showing a proposed model for spreading across uCpG regions by MLL-FPs. (i) In the absence of promoter-bound MLL-AF4, CXXC-mediated recruitment of the fusion protein to uCpG-poor regions in the gene body are not stabilized. (ii) Stable CXXC-mediated recruitment to uCpG-rich promoter regions can stabilize nearby MLL-AF4 recruitment at gene body uCpG regions due to common interactions with complex members such as Menin and ENL, whereas distal recruitment events remain unstable. (iii) Because other CXXC proteins, such as KDM2B, do not interact with complex member such as Menin or ENL, promoter-bound KDM2B is not sufficient to stabilize neighboring CXXC-mediated recruitment to CpG-poor uCpG regions in the gene body.\
(D) Venn diagram showing the overlap between gene targets of super-enhancers, broad H3K4me3 peaks, and spreading MLL-AF4, in SEM cells.\
(E) Heatmap showing ChIP-seq reads of the components indicated at all 149 spreading MLL-AF4 gene targets in SEM cells; scale bar as in (B).\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Spreading MLL-AF4 Targets Show Increased Sensitivity to DOT1L Inhibition\
(A) Venn diagram showing an overlap between H3K79me2-marked genes and upregulated and downregulated genes in SEM cells following treatment with 2 μM EPZ-5676.\
(B) Example ChIP-seq tracks at *CDK6* and nascent RNA-seq in control (0 μM) and 2 μM EPZ-5676-treated SEM cells.\
(C) Pie charts showing the proportion of genes that are significantly downregulated (blue), upregulated (red), or remain unchanged (gray), among H3K79me2-marked genes (left), non-spreading MLL-AF4 gene targets (center), and spreading MLL-AF4 gene targets (right), following treatment of SEM cells with 2 μM EPZ-5676. ^∗∗∗∗^p \< 0.0001, Fisher's exact test.\
(D) Smear plot showing the fold change in gene expression of all genes in SEM cells following treatment with 2 μM EPZ-5676 compared to their expression level (CPM). Black, non-significant change in gene expression; red, differentially expressed gene; green, spreading MLL-AF4 gene targets.\
(E) Box-and-whisker plot showing the median and IQ range of fold change in expression of all significantly downregulated gene targets of non-spreading MLL-AF4 (red) compared to spreading MLL-AF4 (blue), after 2 μM EPZ-5676 treatment in SEM cells. ^∗∗∗∗^p \< 0.0001, Mann-Whitney U test.\
(F) Box-and-whisker plot showing the median and IQ range of fold change in expression of all significantly affected spreading MLL-AF4 (blue), non-spreading MLL-AF4 (red), and non-MLL-AF4 gene targets following siRNA-mediated knockdown of *MLL-AF4* in SEM cells. ^∗∗∗∗^p \< 0.0001, Mann-Whitney U test.\
See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Sensitivity of Spreading Gene Targets Provides a Rationale for Combined Therapy Using DOT1L Inhibitors\
(A) Venn diagram showing the overlap of spreading MLL-AF4 gene targets that are downregulated as measured by nascent RNA-seq following 0.5 μM (blue), 1 μM (red), and 2 μM (green) EPZ-5676 treatment.\
(B) Western blot showing the protein expression of several spreading MLL-AF4 targets and controls in the presence of control, 0.5, 1, or 2 μM EPZ-5676 treatments. Blue and red boxes relate to treatment colors in (A) that led to the lowest level of treatment that resulted in reduced gene transcription.\
(C--E) A cell viability assay of SEMK2 cells treated with a DMSO control, different concentrations of ABT-199 (320, 160, 80, 40, 20, 10, and 5 nM, and DMSO control) alone, or in combination with a 1:10 ratio of either EPZ5676 (C), SGC0946 (D), or MI503 (E) (3,200, 1,600, 800, 400, 200, 100, and 50 nM, and DMSO control).\
(F) A tabular summary of the combination index for the different drug treatments calculated as in [@bib27].](gr7){#fig7}
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